What Are the Challenges in Targeting DNA Polymerases for Cancer Therapy?
One of the main challenges in targeting DNA polymerases is achieving selectivity. Since these enzymes are vital for normal cell division, inhibiting them can lead to toxicity in healthy cells. Additionally, cancer cells often develop resistance to polymerase inhibitors through compensatory mechanisms or additional mutations. Therefore, combining polymerase inhibitors with other therapeutic agents, such as checkpoint inhibitors or DNA damage response inhibitors, may be necessary to enhance efficacy and overcome resistance.
